NEO100 has been granted both Orphan Drug Designation and Fast Track Status by the U.S. Food and Drug Administration (FDA), reinforcing its potential as a significant advancement in the treatment of ...

Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

With our Nasdaq listing in place, we are now focused on advancing our lead clinical asset, JOTROL ™, into a Phase 2a clinical trial in Parkinson’s disease, expanding our presence in Asia ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid ...

Study P300-02-001 is a multicenter, open-label, dose-finding Phase 1b/2a clinical trial to confirm the safety, pharmacokinetics (PK), preliminary antitumor activity, and pharmacodynamics (PD ...

Rockville, Maryland Saturday, April 12, 2025, 18:00 Hrs [IST] ...

Our Phase 1/2a clinical trial has demonstrated that the use of this stem cell population in humans is safe and effective in treating hard to heal diabetic foot ulcers." "We are extremely pleased ...

Moderate Alzheimer’s disease (AD) patients in the trial received the highest dose of troculeucel to date at 6 billion cells per treatment. After 12 months of treatment, both patients who ...

This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials. The TRX103 Phase 1/2a clinical trial is ...

Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating ...